Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Current Assets: 2020-2025

Historic Current Assets for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to $990.7 million.

  • Apellis Pharmaceuticals' Current Assets rose 18.80% to $990.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $990.7 million, marking a year-over-year increase of 18.80%. This contributed to the annual value of $789.0 million for FY2024, which is 2.95% up from last year.
  • Per Apellis Pharmaceuticals' latest filing, its Current Assets stood at $990.7 million for Q3 2025, which was up 31.11% from $755.6 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Current Assets registered a high of $1.1 billion during Q1 2022, and its lowest value of $475.4 million during Q3 2021.
  • Its 3-year average for Current Assets is $834.4 million, with a median of $811.4 million in 2024.
  • As far as peak fluctuations go, Apellis Pharmaceuticals' Current Assets crashed by 35.96% in 2021, and later surged by 74.99% in 2022.
  • Quarterly analysis of 5 years shows Apellis Pharmaceuticals' Current Assets stood at $824.0 million in 2021, then dropped by 12.68% to $719.5 million in 2022, then rose by 6.51% to $766.3 million in 2023, then increased by 2.95% to $789.0 million in 2024, then grew by 18.80% to $990.7 million in 2025.
  • Its last three reported values are $990.7 million in Q3 2025, $755.6 million for Q2 2025, and $727.7 million during Q1 2025.